Clear Focus on Anti-Infective Cures
AiCuris (name derived from 'anti-infective cures') is a pharmaceutical company focused on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases. AiCuris has its roots in Bayer's long history of successful anti-infective drug development. Spun out in 2006 AiCuris owns a broad portfolio of R&D programs, compounds and intellectual property. It´s experienced management team is headed by CEO Prof. Dr. Helga Rübsamen-Schaeff, Bayer´s former Senior Vice President and Head of Anti-Infective Research. Majority investors are Drs. Strüngmann, the founders and previous owners of Hexal, a major German company in the generic drug business.
With its
-
broad and 100 % innovative pipeline from one of the leading pharmaceutical companies in the field of anti-infectives
-
concentration on specialist markets with high medical need
-
team of internationally highly recognized scientists with the knowhow of major pharmaceutical companies
-
support by its majority investors, the Drs. Strüngmann
AiCuris is well positioned to move innovative drugs towards the market for patients with severe, life-threatening infections.
